DeutschNewstral
Article
bizjournals.com on 2016-07-08 23:19
Juno stock plummets, FDA timeline up in air after clinical trial suspension
Related news
- FDA lifts suspension of Juno clinical trialbizjournals.com
- FDA suspends Juno clinical trial after 2 patient deathsbizjournals.com
- MJuno shares up 29% as FDA allows resumption of clinical trial for cancer drugmarketwatch.com
FDA lets Juno restart cancer-treatment trialseattletimes.com- MJuno shares jump after clinical trial of cancer treatment resumedmarketwatch.com
- FDA clears ALung device for clinical trialsbizjournals.com
FDA approves new Baxter clinical nutrition injectionsdailyherald.com- MCatalyst Pharma stock plummets after FDA approves competitor's drugmarketwatch.com
- Juno ends flagship drug trial after deaths and FDA suspensionsbizjournals.com
- FDA lifts clinical hold on AstraZeneca cancer drug studiesbizjournals.com
FDA Finalizes Quality Recommendations for Cannabis in Clinical Investigationsjdsupra.com- FDA puts clinical hold on Inovio's late-stage immunotherapy studybizjournals.com
- MHookipa Pharma jumps 40% after FDA approval of clinical testsmarketwatch.com
- Lengthy Clinical Trial Process Gets Overhaul by FDAjdsupra.com
- MSanthera plummets 35% after FDA denies accelerated DMD drug approvalmarketwatch.com
- Acer Therapeutics stock plummets 80 percent on FDA rejectionbizjournals.com
- MUPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient deathsmarketwatch.com
- Updated FDA COVID-19 Guidance for Conduct of Clinical Trialsjdsupra.com
- FDA Issues Long-Awaited Final Clinical Decision Support Software Guidancejdsupra.com
- FDA Issues Guidance on Clinical Research with Cannabisjdsupra.com